AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6986110
Drug: Inhalant solution
RxNorm normalized name: watermelon allergenic extract 0.1 GM/ML Inhalant Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalant solution of metaproterenol
Trial: 6986110
Drug: 0.5% solution
RxNorm normalized name: VueBlu 0.5% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% solution of isoproterenol
Trial: 20876217
Drug: SBIRT (Screening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBIRT (Screening, Brief Intervention and Referral for Treatment)
Trial: 12694346
Drug: Cholesterol-lowering therapy
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering therapy with simvastatin and ezetimide
Trial: 8612386
Drug: Iron-gluconate formulation
RxNorm normalized name: IRON (AS FERROUS GLUCONATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-gluconate formulation
Trial: 1992306
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (n = 7; maximal dose, 30 mg/kg/day)
Trial: 1992306
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (n = 10; dose range, 2.5 to 12 g/day)
Trial: 25985806
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR 43 mg
Trial: 23357834
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR 86 mg
Trial: 25985806
Drug: Morphine IR
RxNorm normalized name: Morphine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine IR 30 mg
Trial: 25985806
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR 75-100 mg
Trial: 25985806
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR 125-175 mg
Trial: 25985806
Drug: Oxycodone CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone CR 20 mg
Trial: 26437499
Drug: Control (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5% hydroalcohol solution)
Trial: 17323183
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Etidronate (200 mg daily)
Trial: 17323183
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (1 microg alfacalcidol daily)
Trial: 10947691
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl and midazolam
Trial: 1631861
Drug: Creatine phosphate
RxNorm normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine phosphate (10 mmol/L)
Trial: 26003434
Drug: Transdiagnostic Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic Behavior Therapy (TBT)
Trial: 21988544
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation Treatment for Depression (BATD)
Trial: 30203777
Drug: Radix astragali
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radix astragali and Salvia miltiorrhiza injection
Trial: 18452346
Drug: Olanzapine LAI
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine LAI 210 mg/2 weeks
Trial: 12844377
Drug: Retinyl palmitate-containing
RxNorm normalized name: RETINYL PALMITATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl palmitate-containing toothpaste (1 mg/g)
Trial: 8850403
Drug: Intravenous propafenone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone, 1 to 2 mg/kg in a 10‐minute bolus, followed by an infusion of 420 mg in 24 hours.
Trial: 8850403
Drug: Intravenous amiodarone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone, 2.5 to 5 mg/kg in a 10‐minute bolus followed by an infusion of 900 mg in 24 hours.
Trial: 3914368
Drug: Desoximetasone ointment
RxNorm normalized name: Desoximetasone Ointment
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desoximetasone ointment 0.25%
Trial: 27671673
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) implant
Trial: 11561938
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg/day
Trial: 29063516
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg every 12 h
Trial: 26831173
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine administered extradurally
Trial: 26831173
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine administered via femoral and transgluteal sciatic electrolocation-guided nerve block
Trial: 25439693
Drug: Adjuvant capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant capecitabine plus oxaliplatin (8 cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1 for 6 months)
Trial: 20581162
Drug: Oropharyngeal cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal cavity spray of benzydamine hydrochloride (BH) and distilled water on the ET cuff (Group A)
Trial: 20581162
Drug: Both oropharyngeal
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oropharyngeal cavity and ET cuff received BH spray (Group B)
Trial: 3535474
Drug: Acebutolol 200
RxNorm normalized name: acebutolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 200 mg orally twice a day (or 400 mg if weight > 80 kg) from 36 hours after surgery until discharge (usually on the seventh day)
Trial: 3535474
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no beta-blocking drugs)
Trial: 29044968
Drug: DUT‐TAM FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DUT‐TAM FDC therapy (dutasteride 0.5 mg and tamsulosin 0.4 mg)
Trial: 22616853
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of controlled-release melatonin and cognitive-behavioural therapy
Trial: 22616853
Drug: Controlled-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release melatonin
Trial: 9926031
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy
Trial: 22616853
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug treatment
Trial: 116373
Drug: Cefaclor 2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 2, 3, or 4 g with or without 1 g probenecid, administered as single daily doses for three days
Trial: 116373
Drug: Cefaclor 3
RxNorm normalized name: cefaclor 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 3 or 4 g
Trial: 22288893
Drug: Dronabinol (DRO)
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol (DRO) 2.5 mg twice per day for 2 days
Trial: 22288893
Drug: Dronabinol (DRO)
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol (DRO) 5 mg twice per day for 2 days
Trial: 22288893
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) twice per day for 2 days
Trial: 17394959
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate plus N-acetylcysteine (N-AC) infusion started just before contrast injection and continued for 12 h after PCI
Trial: 17394959
Drug: Standard hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hydration protocol consisting of intravenous isotonic saline for 12 h after PCI
Trial: 1636805
Drug: Acute plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute plus maintenance treatment with imipramine (18 months)
Trial: 6394778
Drug: 45% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45% BCAA enriched (low leucine) amino acid solution
Trial: 6394778
Drug: 25% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% BCAA amino acid solution
Trial: 6394778
Drug: 45% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45% BCAA enriched (high leucine) amino acid solution
Trial: 22856593
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg by mouth twice a day for 7 days)
Trial: 9736552
Drug: Stavudine (d4T)
RxNorm normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine (d4T) 70 mg in fasting state
Trial: 9736552
Drug: Stavudine (d4T)
RxNorm normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine (d4T) 70 mg 1 hour before a meal
Trial: 9736552
Drug: Stavudine (d4T)
RxNorm normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine (d4T) 70 mg 5 minutes after a high-fat breakfast
Trial: 26909845
Drug: Grape intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape intake of 50 g/day
Trial: 21766228
Drug: GTP (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTP (500 mg GTP/day)
Trial: 17275908
Drug: Intravitreal 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal 10% C3F8 infusion at the end of surgery
Trial: 10681809
Drug: Lentinan treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentinan treatment for 2 months
Trial: 7655202
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium (+H)
Trial: 7655202
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin (-H)
Trial: 9963
Drug: N-desmethyldiazepam (nordiazepam)
RxNorm normalized name: N-ethylurea
DrugBank: Nordazepam (DB14028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-desmethyldiazepam (nordiazepam) 5 mg
Trial: 31094793
Drug: Low volume/high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume/high concentration (LVHC) - 0.1 mL·kg of 0.4% levobupivacaine
Trial: 31094793
Drug: High volume/low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume/low concentration (HVLC) - 0.2 mL·kg of 0.2% levobupivacaine
Trial: 18575077
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/day
Trial: 15683500
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg/day
Trial: 18635707
Drug: Immediate-release d-amphetamine
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release d-amphetamine sulphate 20 mg
Trial: 11435337
Drug: Beta-blocker atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker atenolol (100 mg once a day)
Trial: 8117122
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (initial static Crs >= 1.8 ml/cm H2O/m)
Trial: 31111882
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment (Control Group)
Trial: 31111882
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (TGs)
Trial: 28035541
Drug: EAA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAA plus leflflunomide and methotrexate (30 g/d)
Trial: 21667450
Drug: Long-term psychoanalytic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term psychoanalytic treatment
Trial: 19304891
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg bevirimat solution delivered to the proximal small bowel via Enterion capsule
Trial: 19304891
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg bevirimat solution delivered to the distal small bowel via Enterion capsule
Trial: 8698959
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy focusing on interpersonal and developmental vulnerabilities
Trial: 8698959
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy with a developmental focus
Trial: 154426
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg b.i.d.)
Trial: 2744064
Drug: temazepam 20
RxNorm normalized name: temazepam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temazepam 20 mg
Trial: 16923101
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg parecoxib
Trial: 20427369
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g acetaminophen
Trial: 20427369
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg parecoxib plus 5 g acetaminophen
Trial: 10210023
Drug: Felbamate (FBM)
RxNorm normalized name: Felbamate
DrugBank: Felbamate (DB00949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felbamate (FBM) in combination with Valproic Acid (VPA)
Trial: 1877476
Drug: Intravenous urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous urokinase plus heparin
Trial: 14564321
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone
Trial: 6311782
Drug: mezlocillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mezlocillin (4 g iv 6‐hourly) plus cefotaxime (2 g iv 8‐hourly)
Trial: 17627725
Drug: Sildenafil (Viagra),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (Viagra), up to one study tablet per day for 6 months
Trial: 2891224
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg bid
Trial: 6108729
Drug: Temazepam 30
RxNorm normalized name: temazepam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 30 mg
Trial: 27921320
Drug: Amiselimod 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiselimod 0.4 mg
Trial: 29570538
Drug: Reboxetine (REB)
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (REB) 8 mg
Trial: 21624418
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of CPG 7909 alone
Trial: 21624418
Drug: BioThrax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioThrax plus 1 mg of CPG 7909
Trial: 12577250
Drug: Subcutaneous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous amifostine
Trial: 8160899
Drug: Gentamicin/Clindamycin (G/C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin/Clindamycin (G/C)
Trial: 21118743
Drug: Armodafinil 200
RxNorm normalized name: armodafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 200 mg single dose
Trial: 21118743
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg single dose
Trial: 21118743
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily armodafinil 200 mg doses
Trial: 10847311
Drug: No experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No experimental treatment (control)
Trial: 8635429
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) including carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB), valproate (VPA)
Trial: 15847747
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs)
Trial: 3904437
Drug: Isoxicam 200
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoxicam 200 mg per day
Trial: 3904437
Drug: Isoxicam dosages
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoxicam dosages ranging from 200 to 600 mg per day
Trial: 26670665
Drug: Tibolone (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (1.25 mg/day for 24 weeks)
Trial: 26670665
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without hormone replacement therapy)
Trial: 20822038
Drug: Fentanyl pectin
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl pectin nasal spray (FPNS)
Trial: 16270403
Drug: Lamivudine only
RxNorm normalized name: Lamivudine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine only (100 mg daily)
Trial: 27914653
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy (target INR of 2.0 to 3.0)
Trial: 27914653
Drug: Aspirin 150mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 150mg daily
Trial: 3897558
Drug: Oltipraz 15
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 15 mg/kg
Trial: 3897558
Drug: Oltipraz 25
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 25 mg/kg
Trial: 3897558
Drug: Divided dose
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided dose taken 6 hours apart
Trial: 30781461
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no PRP injection)
Trial: 16104039
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (Day 1: OND 8 mg and DEX 20 mg before chemotherapy and OND 8 mg 8 hrs later; Days 2-3: OND 8 mg twice per day)
Trial: 12115238
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 0.15 mg/kg/week (increased to 0.25 mg/kg/week, max 15 mg)
Trial: 31882409
Drug: Once-weekly exenatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly exenatide therapy
Trial: 30777794
Drug: TP (thalidomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP (thalidomide 100 mg/d for ≤12 months/until disease progression; prednisolone 50 mg on alternate days indefinitely/until disease progression; n=100)
Trial: 30777794
Drug: VTP (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTP (subcutaneous bortezomib 1.3 mg/m2 every 2 weeks for 32 weeks, plus TP; n=103)
Trial: 11978956
Drug: Metoprolol sustained-release
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol sustained-release treatment
Trial: 2275356
Drug: Oral metyrapone
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metyrapone tartrate
Trial: 29149958
Drug: Immediate-release tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tacrolimus
Trial: 18558914
Drug: Coordinated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coordinated care plan including treatment for depression and anxiety disorders, containment strategy for somatisation, and service coordinator-assisted self-management.
Trial: 14750201
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Control group)
Trial: 12524411
Drug: 0.4% GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% GTN ointment
Trial: 2014460
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.45 mg/kg
Trial: 2014460
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam 0.15 mg/kg
Trial: 2014460
Drug: Oral trimeprazine
RxNorm normalized name: trimeprazine
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral trimeprazine tartrate 2 mg/kg, methadone 0.1 mg/kg, droperidol 0.15 mg/kg (TMD)
Trial: 22838970
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors
Trial: 7887119
Drug: Clonidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (4 micrograms.kg‐1 loading dose in 30 min, maintained with 1 microgram.kg‐1.h‐1 infusion)
Trial: 7887119
Drug: Labetalol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (0.2 mg.kg‐1 loading dose followed by 0.1 mg.kg‐1.h‐1 infusion)